Business Wire

SEOUL-VIOSYS

Share
Seoul Viosys’ Violeds, the World’s First UV LED Technology Proven to Sterilize New Coronaviruses, Has Been Adopted by Gree, the Leading Chinese Manufacturer of Air Conditioners

Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that its ultraviolet LED Violeds technology – the world’s first UV LED technology proven to sterilize new coronaviruses – has been adopted for the new “Fresh Air” brand of air conditioners produced by Gree Electric Appliances Inc. (Gree), the largest Chinese manufacturer of air conditioners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005326/en/

The Violeds UV LED technology adopted for the Gree “Fresh Air” air conditioner is a differentiated UV technology that provides robust disinfection on the surface of evaporator, as well as sterilization of any indoor airborne contaminants drawn into the air conditioner, including various harmful viruses and bacteria, ensuring that fresh air is continuously discharged. Conventional household air conditioners typically draw outside air into the AC unit, and discharge that air back into the interior after cooling and filtering, where it is continuously recirculated. This recirculation of indoor air may cause a higher risk of infection through aerosol transmission when viruses are present.

Through the results of testing by Guangzhou Institute of Microbiology in China (CGMT), Gree demonstrates that its new “Fresh Air” air conditioner with Violeds UV LED technology has the performance to sterilize 99.15% of viruses and bacteria, 98% of enteroviruses such as EV71 and H1N1, and 99% of staphylococcus albus bacteria. In addition, according to the results of testing conducted in April and May 2020 by the research group of Korea University, Violeds UV LED technology has been proven to sterilize 99.9% of the new coronavirus in 30 seconds. Seoul Viosys provides major customers with optimized UV LED solutions based on these successful testing results.

“Since air conditioning systems operate by circulating indoor air drawn in and discharged again, aerosol transmission is a concern when using these systems. In South Korea, health authorities rolled out a new guideline for citizens to prevent aerosol transmission, which included advising people to open windows every two hours when using their air conditioners,” said Chae Hon Kim, executive vice president of Seoul Viosys. “We offer an optimized solution to simultaneously enable disinfection of viruses in air, as well as air purification by disinfecting the air drawn into air conditioner and eliminating viruses in air using Violeds technology. As more applications adopt the Violeds technology to support healthy life, the cost of UV LEDs is anticipated to be reduced to a level closer to visible white LEDs.”

“Seoul Viosys’ Violeds technology has been adopted not only by the Chinese AC manufacturer Gree, but also by RGF Environmental Group, the leading in-duct air treatment supplier in the U.S. As a result of receiving production approval to supply Violeds products to these two leading global companies, Violeds UV LEDs have clearly been recognized as essential technology for air purifiers and air conditioning systems,” added Kim.

Violeds optical semiconductor technology is a new concept of clean technology developed by Seoul Viosys, starting with a 2005 collaboration with SETi in the U.S. Seoul Viosys’ UV LEDs are used in more than 4,000 patented technology brands worldwide to prevent viruses and bacteria from proliferating through exposure to ultraviolet light. With more than 1,000 patents secured and verified for the application of Violeds technology, the company has succeeded in extending its lifespan of its UV LED devices to 50,000 hours, and they have been widely adopted for air conditioners, air purifiers, water purifiers and multi-disinfection devices.

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release

Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd

FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release

Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release

The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye